We Are Crinetics


Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest


Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

Crinetics will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL.

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and an aggregate of 101,800 restricted stock unit awards to 35 new non-executive employees.

Discovery IND-enabling Phase 1 Phase 2 Phase 3 Approved
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-Dependent Cushing's Syndrome
CRN09682, Non-Peptide Drug Conjugate
NETs and SST2-Expressing Tumors
PTH Antagonist
Hyperparathyroidism
TSH Antagonist
Graves' Disease, TED
SST3 Agonist
Polycystic Kidney Disease
SST5 Agonist
Hyperinsulinism
Oral GLP-1 Nonpeptide
Diabetes, Obesity
Oral GIP Nonpeptide
Diabetes, Obesity
Radionetics
Targeted Radiotherapy for Multiple Solid-Tumors
Discovery IND-enabling Phase 1 Phase 2 Phase 3 Approved
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-Dependent Cushing's Syndrome
CRN09682, Non-Peptide Drug Conjugate
NETs and SST2-Expressing Tumors
PTH Antagonist
Hyperparathyroidism
SST3 Agonist
Polycystic Kidney Disease
SST5 Agonist
Hyperinsulinism
TSH Antagonist
Graves' Disease, TED
Oral GLP-1 Nonpeptide
Diabetes, Obesity
Oral GIP Nonpeptide
Diabetes, Obesity
Radionetics
Targeted Radiotherapy for Multiple Solid-Tumors